A race for an Ebola vaccine: Promises and obstacles

Trends in Microbiology

Volumn 23, Issue 2, 2015, Pages 65-66

  Cooper, Christopher L ^a   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Durable immunity; Ebola; FDA clinical trial; Immune correlates; Vaccine

Indexed keywords

ADENOVIRUS VACCINE; ADENOVIRUS VECTOR; EBOLA VACCINE; VIRUS GLYCOPROTEIN;

ANTIBODY TITER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; EPIDEMIC; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICAL SOCIETY; NONHUMAN; PUBLISHING; SHORT SURVEY; VACCINE PRODUCTION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION;

PRIMATES;

EID: 84964305201     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2014.12.005     Document Type: Short Survey

References (10)

1. Stanley D.A., et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat. Med. 2014, 20:1126-1129.
2. Kuhn J.H., et al. Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch. Virol. 2013, 158:301-311.
3. Geisbert T.W., Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J. Infect. Dis. 2011, 204(Suppl. 3):S1075-S1081.
4. Marzi A., Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert Rev. Vaccines 2014, 13:521-531.
5. Martins K.A., et al. Characterization of a putative filovirus vaccine: virus-like particles. Virol. Sin. 2013, 28:65-70.
6. Bradfute S.B., Bavari S. Correlates of immunity to filovirus infection. Viruses 2011, 3:982-1000.
7. Geisbert T.W., et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J. Virol. 2011, 85:4222-4233.
8. Ledgerwood J.E., et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010, 29:304-313.
9. Mire C.E., et al. Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS ONE 2014, 9:e94355.
10. Wong G., et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine 2014, 32:5722-5729.